1 |
Zou LR, Ruan F, Huang MX, Liang LJ, Huang HT, Hong ZS, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020 ;382(12):1177-9.
|
2 |
Ki YJ, Jeong YH. Thrombosis and anticoagulation in east asian patients with COVID-19: another phenotype of "East Asian Paradox". JACC Asia. 2022 ;2(7):908-11.
|
3 |
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017 ;43(3):304-77.
|
4 |
Venet F, Schilling J, Cazalis MA, Demaret J, Poujol F, Girardot T, et al. Modulation of LILRB 2 protein and mRNA expressions in septic shock patients and after ex vivo lipopolysaccharide stimulation. Hum Immunol. 2017 ;78(5-6):441-50.
|
5 |
Mick E, Kamm J, Pisco AO, Ratnasiri K, Babik JM, Castañeda G, et al. Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses. Nat Commun. 2020;11:5854.
|
6 |
Chen L, Zhang YH, Wang SP, Zhang YH, Huang T, Cai YD. Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways. PLoS One. 2017 ;12(9):e0184129.
|
7 |
Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021 ;49(D1):D605-D612.
|
8 |
Wu ZY, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 ;323(13):1239-42.
|
9 |
Algarni AS, Alamri NM, Khayat NZ, Alabdali RA, Alsubhi RS, Alghamdi SH. Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. World J Pediatr. 2022 ;18(2):83-90.
|
10 |
Granier C, de Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017 ;2(2):e000213.
|
11 |
Zou M, Su XY, Wang LY, Yi XC, Qiu Y, Yin XR, et al. The molecular mechanism of multiple organ dysfunction and targeted intervention of COVID-19 based on time-order transcriptomic analysis. Front Immunol. 2021;12:729776.
|
12 |
Shin GC, Kang HS, Lee AR, Kim KH. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. Autophagy. 2016 ;12(12):2451-66.
|
13 |
Zhang Q, Bastard P, Liu ZY, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 ;370(6515):eabd4570.
|
14 |
La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/ 2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020 ;34(7):1805-15.
|
15 |
Ahmed SSSJ, Paramasivam P, Kamath M, Sharma A, Rome S, Murugesan R. Genetic exchange of lung-derived exosome to brain causing neuronal changes on COVID-19 infection. Mol Neurobiol. 2021 ;58(10):5356-68.
|